Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Nurix Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
NRIX
Nasdaq
2836
www.nurixtx.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Nurix Therapeutics, Inc.
Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
- Feb 4th, 2025 12:00 pm
Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Lags Revenue Estimates
- Jan 28th, 2025 10:10 pm
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update
- Jan 28th, 2025 9:00 pm
Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer
- Jan 22nd, 2025 12:00 pm
We Think Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Drive Business Growth
- Jan 19th, 2025 12:45 pm
Nurix Therapeutics Outlines 2025 Goals and Objectives for Advancement of Its Robust Pipeline in Cancer and Autoimmune Diseases
- Jan 13th, 2025 12:00 pm
Strength Seen in SpringWorks Therapeutics (SWTX): Can Its 6.0% Jump Turn into More Strength?
- Jan 8th, 2025 8:36 am
Nurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
- Jan 6th, 2025 12:00 pm
Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom’s Macroglobulinemia
- Dec 19th, 2024 12:00 pm
Is Nurix Therapeutics (NRIX) the Worst ARK Stock to Buy According to Short Sellers?
- Dec 11th, 2024 5:05 pm
Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting
- Dec 9th, 2024 11:00 pm
Why Is Nurix Therapeutics, Inc. (NRIX) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?
- Dec 4th, 2024 6:10 pm
Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting
- Dec 2nd, 2024 12:00 pm
Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
- Nov 25th, 2024 12:00 pm
Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia
- Nov 20th, 2024 9:00 pm
Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024
- Nov 17th, 2024 3:30 pm
Nurix Therapeutics Announces Presentations at the 66th American Society of Hematology (ASH) Annual Meeting
- Nov 5th, 2024 2:00 pm
Nurix Therapeutics to Participate in Upcoming Investor Conferences
- Oct 31st, 2024 11:00 am
Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit
- Oct 21st, 2024 8:00 pm
Nurix Therapeutics’ NX-5948 shows promise in Waldenstrom’s macroglobulinaemia trial
- Oct 21st, 2024 9:45 am
Scroll